1269702-96-6

Basic information

• Product Name: 4-CHLORO-1-(3-FLUOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDINE
• Synonyms: 4-CHLORO-1-(3-FLUOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDINE
• CAS NO: 1269702-96-6
• Molecular Formula: C11H6ClFN4
• Molecular Weight: 248.64
• Mol File: 1269702-96-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLORO-1-(3-FLUOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-1-(3-FLUOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDINE(1269702-96-6)
• EPA Substance Registry System: 4-CHLORO-1-(3-FLUOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDINE(1269702-96-6)

Safety Data

• Hazardous Substances Data: 1269702-96-6(Hazardous Substances Data)

Upstream product

• 51516-71-3 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carbonitrile 

Relevant articles and documents

Identification of novel GLUT inhibitors

The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.

GLUCOSE TRANSPORT INHIBITORS

The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS

The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Ar1) determined this to be a tight binding region with little room for modification. As predicted from the model, a large variety of modifications could be incorporated into the hydrazone aryl ring. This work led to GSK-3 inhibitors in the low nano-molar range.